CANCER-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1016246, encodeId=859510162460e, content=偏重的研究方向：肿瘤 经验分享：本人新手，刚要投这个杂志，想问下各位前辈这个杂志有格式要求吗，感觉找了好久没有找到具体的格式要求，大家格式都是怎么改的呢？看以往的文献吗？急急急急！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Fri Sep 10 08:02:18 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800895, encodeId=a8bd800895b8, content=有谁投中过这个杂志？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Jul 02 14:23:56 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904388, encodeId=32e5904388c5, content=今年这个期刊审稿快吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Dec 02 21:00:52 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589636, encodeId=2a1858963688, content=有要求字数要在5000以内吗凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!凱凱 2019-01-31 22:31:00 发表: submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, beContent=凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/edSY1qepX1ZvQ2va1f5T6pokTtL8znN1iclTQibflhWLyNAhELSEiamneoz9dNPY0iaxwf4bAiaFd27Aaicb8Ia9Qo4A/132, createdBy=0a5e2141609, createdName=豆们, createdTime=Fri Apr 24 00:00:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588315, encodeId=e23658831541, content=接收率这么高，约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrAfzjy5NbB6uHQuic53jMiazG25xatSfmLq4T2qc2T5WJuRhIicFcMDMTnLk5Awg75tic4NyBtawybmpCCiajrPVHg/132, createdBy=508c5311913, createdName=杨药师, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583184, encodeId=5a5458318457, content=应该都是约稿吧771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, beContent=771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18c096953, createdName=caowei561521, createdTime=Sun Jan 12 00:00:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581970, encodeId=ccb25819e06b, content=这个命中率是有问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f62b2484088, createdName=12464da8m54(暂无昵称), createdTime=Sun Dec 22 00:00:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581471, encodeId=aaf95814e1f5, content=请问有前辈在这本杂志上发过综述吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60882530625, createdName=771128365_61423734, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581285, encodeId=6e27581285b4, content=3400ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , beContent=ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581321, encodeId=1b33581321ce, content=你投过吗，处理稿件很慢么？一一一多 2019-12-11 00:00:00 发表: 3400, beContent=一一一多 2019-12-11 00:00:00 发表: 3400, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]

2021-09-10 ms7000002132756283

偏重的研究方向：肿瘤
经验分享：本人新手，刚要投这个杂志，想问下各位前辈这个杂志有格式要求吗，感觉找了好久没有找到具体的格式要求，大家格式都是怎么改的呢？看以往的文献吗？急急急急！！

72 0

[GetPortalCommentsPageByObjectIdResponse(id=1016246, encodeId=859510162460e, content=偏重的研究方向：肿瘤 经验分享：本人新手，刚要投这个杂志，想问下各位前辈这个杂志有格式要求吗，感觉找了好久没有找到具体的格式要求，大家格式都是怎么改的呢？看以往的文献吗？急急急急！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Fri Sep 10 08:02:18 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800895, encodeId=a8bd800895b8, content=有谁投中过这个杂志？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Jul 02 14:23:56 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904388, encodeId=32e5904388c5, content=今年这个期刊审稿快吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Dec 02 21:00:52 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589636, encodeId=2a1858963688, content=有要求字数要在5000以内吗凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!凱凱 2019-01-31 22:31:00 发表: submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, beContent=凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/edSY1qepX1ZvQ2va1f5T6pokTtL8znN1iclTQibflhWLyNAhELSEiamneoz9dNPY0iaxwf4bAiaFd27Aaicb8Ia9Qo4A/132, createdBy=0a5e2141609, createdName=豆们, createdTime=Fri Apr 24 00:00:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588315, encodeId=e23658831541, content=接收率这么高，约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrAfzjy5NbB6uHQuic53jMiazG25xatSfmLq4T2qc2T5WJuRhIicFcMDMTnLk5Awg75tic4NyBtawybmpCCiajrPVHg/132, createdBy=508c5311913, createdName=杨药师, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583184, encodeId=5a5458318457, content=应该都是约稿吧771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, beContent=771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18c096953, createdName=caowei561521, createdTime=Sun Jan 12 00:00:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581970, encodeId=ccb25819e06b, content=这个命中率是有问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f62b2484088, createdName=12464da8m54(暂无昵称), createdTime=Sun Dec 22 00:00:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581471, encodeId=aaf95814e1f5, content=请问有前辈在这本杂志上发过综述吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60882530625, createdName=771128365_61423734, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581285, encodeId=6e27581285b4, content=3400ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , beContent=ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581321, encodeId=1b33581321ce, content=你投过吗，处理稿件很慢么？一一一多 2019-12-11 00:00:00 发表: 3400, beContent=一一一多 2019-12-11 00:00:00 发表: 3400, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]

2020-07-02 钱湖鑫

有谁投中过这个杂志？

132 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1016246, encodeId=859510162460e, content=偏重的研究方向：肿瘤 经验分享：本人新手，刚要投这个杂志，想问下各位前辈这个杂志有格式要求吗，感觉找了好久没有找到具体的格式要求，大家格式都是怎么改的呢？看以往的文献吗？急急急急！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Fri Sep 10 08:02:18 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800895, encodeId=a8bd800895b8, content=有谁投中过这个杂志？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Jul 02 14:23:56 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904388, encodeId=32e5904388c5, content=今年这个期刊审稿快吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Dec 02 21:00:52 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589636, encodeId=2a1858963688, content=有要求字数要在5000以内吗凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!凱凱 2019-01-31 22:31:00 发表: submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, beContent=凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/edSY1qepX1ZvQ2va1f5T6pokTtL8znN1iclTQibflhWLyNAhELSEiamneoz9dNPY0iaxwf4bAiaFd27Aaicb8Ia9Qo4A/132, createdBy=0a5e2141609, createdName=豆们, createdTime=Fri Apr 24 00:00:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588315, encodeId=e23658831541, content=接收率这么高，约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrAfzjy5NbB6uHQuic53jMiazG25xatSfmLq4T2qc2T5WJuRhIicFcMDMTnLk5Awg75tic4NyBtawybmpCCiajrPVHg/132, createdBy=508c5311913, createdName=杨药师, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583184, encodeId=5a5458318457, content=应该都是约稿吧771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, beContent=771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18c096953, createdName=caowei561521, createdTime=Sun Jan 12 00:00:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581970, encodeId=ccb25819e06b, content=这个命中率是有问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f62b2484088, createdName=12464da8m54(暂无昵称), createdTime=Sun Dec 22 00:00:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581471, encodeId=aaf95814e1f5, content=请问有前辈在这本杂志上发过综述吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60882530625, createdName=771128365_61423734, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581285, encodeId=6e27581285b4, content=3400ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , beContent=ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581321, encodeId=1b33581321ce, content=你投过吗，处理稿件很慢么？一一一多 2019-12-11 00:00:00 发表: 3400, beContent=一一一多 2019-12-11 00:00:00 发表: 3400, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]

2020-12-02 牵牛花开

今年这个期刊审稿快吗？

97 0

[GetPortalCommentsPageByObjectIdResponse(id=1016246, encodeId=859510162460e, content=偏重的研究方向：肿瘤 经验分享：本人新手，刚要投这个杂志，想问下各位前辈这个杂志有格式要求吗，感觉找了好久没有找到具体的格式要求，大家格式都是怎么改的呢？看以往的文献吗？急急急急！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Fri Sep 10 08:02:18 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800895, encodeId=a8bd800895b8, content=有谁投中过这个杂志？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Jul 02 14:23:56 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904388, encodeId=32e5904388c5, content=今年这个期刊审稿快吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Dec 02 21:00:52 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589636, encodeId=2a1858963688, content=有要求字数要在5000以内吗凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!凱凱 2019-01-31 22:31:00 发表: submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, beContent=凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/edSY1qepX1ZvQ2va1f5T6pokTtL8znN1iclTQibflhWLyNAhELSEiamneoz9dNPY0iaxwf4bAiaFd27Aaicb8Ia9Qo4A/132, createdBy=0a5e2141609, createdName=豆们, createdTime=Fri Apr 24 00:00:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588315, encodeId=e23658831541, content=接收率这么高，约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrAfzjy5NbB6uHQuic53jMiazG25xatSfmLq4T2qc2T5WJuRhIicFcMDMTnLk5Awg75tic4NyBtawybmpCCiajrPVHg/132, createdBy=508c5311913, createdName=杨药师, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583184, encodeId=5a5458318457, content=应该都是约稿吧771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, beContent=771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18c096953, createdName=caowei561521, createdTime=Sun Jan 12 00:00:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581970, encodeId=ccb25819e06b, content=这个命中率是有问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f62b2484088, createdName=12464da8m54(暂无昵称), createdTime=Sun Dec 22 00:00:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581471, encodeId=aaf95814e1f5, content=请问有前辈在这本杂志上发过综述吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60882530625, createdName=771128365_61423734, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581285, encodeId=6e27581285b4, content=3400ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , beContent=ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581321, encodeId=1b33581321ce, content=你投过吗，处理稿件很慢么？一一一多 2019-12-11 00:00:00 发表: 3400, beContent=一一一多 2019-12-11 00:00:00 发表: 3400, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]

2020-04-24 豆们

有要求字数要在5000以内吗凱凱 2019-01-31 发表::
研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!凱凱 2019-01-31 22:31:00 发表:
submitted: 2018-8-3
2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可
Revised: 2019-1-16
Accepted: 2019-1-28
值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!

凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!

125 0

[GetPortalCommentsPageByObjectIdResponse(id=1016246, encodeId=859510162460e, content=偏重的研究方向：肿瘤 经验分享：本人新手，刚要投这个杂志，想问下各位前辈这个杂志有格式要求吗，感觉找了好久没有找到具体的格式要求，大家格式都是怎么改的呢？看以往的文献吗？急急急急！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Fri Sep 10 08:02:18 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800895, encodeId=a8bd800895b8, content=有谁投中过这个杂志？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Jul 02 14:23:56 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904388, encodeId=32e5904388c5, content=今年这个期刊审稿快吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Dec 02 21:00:52 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589636, encodeId=2a1858963688, content=有要求字数要在5000以内吗凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!凱凱 2019-01-31 22:31:00 发表: submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, beContent=凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/edSY1qepX1ZvQ2va1f5T6pokTtL8znN1iclTQibflhWLyNAhELSEiamneoz9dNPY0iaxwf4bAiaFd27Aaicb8Ia9Qo4A/132, createdBy=0a5e2141609, createdName=豆们, createdTime=Fri Apr 24 00:00:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588315, encodeId=e23658831541, content=接收率这么高，约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrAfzjy5NbB6uHQuic53jMiazG25xatSfmLq4T2qc2T5WJuRhIicFcMDMTnLk5Awg75tic4NyBtawybmpCCiajrPVHg/132, createdBy=508c5311913, createdName=杨药师, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583184, encodeId=5a5458318457, content=应该都是约稿吧771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, beContent=771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18c096953, createdName=caowei561521, createdTime=Sun Jan 12 00:00:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581970, encodeId=ccb25819e06b, content=这个命中率是有问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f62b2484088, createdName=12464da8m54(暂无昵称), createdTime=Sun Dec 22 00:00:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581471, encodeId=aaf95814e1f5, content=请问有前辈在这本杂志上发过综述吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60882530625, createdName=771128365_61423734, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581285, encodeId=6e27581285b4, content=3400ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , beContent=ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581321, encodeId=1b33581321ce, content=你投过吗，处理稿件很慢么？一一一多 2019-12-11 00:00:00 发表: 3400, beContent=一一一多 2019-12-11 00:00:00 发表: 3400, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]

2020-04-06 杨药师

接收率这么高，约稿吗？

126 0

[GetPortalCommentsPageByObjectIdResponse(id=1016246, encodeId=859510162460e, content=偏重的研究方向：肿瘤 经验分享：本人新手，刚要投这个杂志，想问下各位前辈这个杂志有格式要求吗，感觉找了好久没有找到具体的格式要求，大家格式都是怎么改的呢？看以往的文献吗？急急急急！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Fri Sep 10 08:02:18 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800895, encodeId=a8bd800895b8, content=有谁投中过这个杂志？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Jul 02 14:23:56 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904388, encodeId=32e5904388c5, content=今年这个期刊审稿快吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Dec 02 21:00:52 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589636, encodeId=2a1858963688, content=有要求字数要在5000以内吗凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!凱凱 2019-01-31 22:31:00 发表: submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, beContent=凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/edSY1qepX1ZvQ2va1f5T6pokTtL8znN1iclTQibflhWLyNAhELSEiamneoz9dNPY0iaxwf4bAiaFd27Aaicb8Ia9Qo4A/132, createdBy=0a5e2141609, createdName=豆们, createdTime=Fri Apr 24 00:00:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588315, encodeId=e23658831541, content=接收率这么高，约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrAfzjy5NbB6uHQuic53jMiazG25xatSfmLq4T2qc2T5WJuRhIicFcMDMTnLk5Awg75tic4NyBtawybmpCCiajrPVHg/132, createdBy=508c5311913, createdName=杨药师, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583184, encodeId=5a5458318457, content=应该都是约稿吧771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, beContent=771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18c096953, createdName=caowei561521, createdTime=Sun Jan 12 00:00:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581970, encodeId=ccb25819e06b, content=这个命中率是有问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f62b2484088, createdName=12464da8m54(暂无昵称), createdTime=Sun Dec 22 00:00:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581471, encodeId=aaf95814e1f5, content=请问有前辈在这本杂志上发过综述吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60882530625, createdName=771128365_61423734, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581285, encodeId=6e27581285b4, content=3400ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , beContent=ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581321, encodeId=1b33581321ce, content=你投过吗，处理稿件很慢么？一一一多 2019-12-11 00:00:00 发表: 3400, beContent=一一一多 2019-12-11 00:00:00 发表: 3400, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]

2020-01-12 caowei561521

应该都是约稿吧771128365_61423734 2019-12-14 00:00:00 发表:
请问有前辈在这本杂志上发过综述吗？

771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？

118 0

[GetPortalCommentsPageByObjectIdResponse(id=1016246, encodeId=859510162460e, content=偏重的研究方向：肿瘤 经验分享：本人新手，刚要投这个杂志，想问下各位前辈这个杂志有格式要求吗，感觉找了好久没有找到具体的格式要求，大家格式都是怎么改的呢？看以往的文献吗？急急急急！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Fri Sep 10 08:02:18 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800895, encodeId=a8bd800895b8, content=有谁投中过这个杂志？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Jul 02 14:23:56 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904388, encodeId=32e5904388c5, content=今年这个期刊审稿快吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Dec 02 21:00:52 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589636, encodeId=2a1858963688, content=有要求字数要在5000以内吗凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!凱凱 2019-01-31 22:31:00 发表: submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, beContent=凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/edSY1qepX1ZvQ2va1f5T6pokTtL8znN1iclTQibflhWLyNAhELSEiamneoz9dNPY0iaxwf4bAiaFd27Aaicb8Ia9Qo4A/132, createdBy=0a5e2141609, createdName=豆们, createdTime=Fri Apr 24 00:00:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588315, encodeId=e23658831541, content=接收率这么高，约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrAfzjy5NbB6uHQuic53jMiazG25xatSfmLq4T2qc2T5WJuRhIicFcMDMTnLk5Awg75tic4NyBtawybmpCCiajrPVHg/132, createdBy=508c5311913, createdName=杨药师, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583184, encodeId=5a5458318457, content=应该都是约稿吧771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, beContent=771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18c096953, createdName=caowei561521, createdTime=Sun Jan 12 00:00:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581970, encodeId=ccb25819e06b, content=这个命中率是有问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f62b2484088, createdName=12464da8m54(暂无昵称), createdTime=Sun Dec 22 00:00:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581471, encodeId=aaf95814e1f5, content=请问有前辈在这本杂志上发过综述吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60882530625, createdName=771128365_61423734, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581285, encodeId=6e27581285b4, content=3400ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , beContent=ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581321, encodeId=1b33581321ce, content=你投过吗，处理稿件很慢么？一一一多 2019-12-11 00:00:00 发表: 3400, beContent=一一一多 2019-12-11 00:00:00 发表: 3400, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]

2019-12-22 12464da8m54(暂无昵称)

这个命中率是有问题吗

120 0

[GetPortalCommentsPageByObjectIdResponse(id=1016246, encodeId=859510162460e, content=偏重的研究方向：肿瘤 经验分享：本人新手，刚要投这个杂志，想问下各位前辈这个杂志有格式要求吗，感觉找了好久没有找到具体的格式要求，大家格式都是怎么改的呢？看以往的文献吗？急急急急！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Fri Sep 10 08:02:18 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800895, encodeId=a8bd800895b8, content=有谁投中过这个杂志？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Jul 02 14:23:56 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904388, encodeId=32e5904388c5, content=今年这个期刊审稿快吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Dec 02 21:00:52 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589636, encodeId=2a1858963688, content=有要求字数要在5000以内吗凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!凱凱 2019-01-31 22:31:00 发表: submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, beContent=凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/edSY1qepX1ZvQ2va1f5T6pokTtL8znN1iclTQibflhWLyNAhELSEiamneoz9dNPY0iaxwf4bAiaFd27Aaicb8Ia9Qo4A/132, createdBy=0a5e2141609, createdName=豆们, createdTime=Fri Apr 24 00:00:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588315, encodeId=e23658831541, content=接收率这么高，约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrAfzjy5NbB6uHQuic53jMiazG25xatSfmLq4T2qc2T5WJuRhIicFcMDMTnLk5Awg75tic4NyBtawybmpCCiajrPVHg/132, createdBy=508c5311913, createdName=杨药师, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583184, encodeId=5a5458318457, content=应该都是约稿吧771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, beContent=771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18c096953, createdName=caowei561521, createdTime=Sun Jan 12 00:00:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581970, encodeId=ccb25819e06b, content=这个命中率是有问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f62b2484088, createdName=12464da8m54(暂无昵称), createdTime=Sun Dec 22 00:00:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581471, encodeId=aaf95814e1f5, content=请问有前辈在这本杂志上发过综述吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60882530625, createdName=771128365_61423734, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581285, encodeId=6e27581285b4, content=3400ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , beContent=ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581321, encodeId=1b33581321ce, content=你投过吗，处理稿件很慢么？一一一多 2019-12-11 00:00:00 发表: 3400, beContent=一一一多 2019-12-11 00:00:00 发表: 3400, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]

2019-12-14 771128365_61423734

请问有前辈在这本杂志上发过综述吗？

108 0

[GetPortalCommentsPageByObjectIdResponse(id=1016246, encodeId=859510162460e, content=偏重的研究方向：肿瘤 经验分享：本人新手，刚要投这个杂志，想问下各位前辈这个杂志有格式要求吗，感觉找了好久没有找到具体的格式要求，大家格式都是怎么改的呢？看以往的文献吗？急急急急！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Fri Sep 10 08:02:18 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800895, encodeId=a8bd800895b8, content=有谁投中过这个杂志？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Jul 02 14:23:56 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904388, encodeId=32e5904388c5, content=今年这个期刊审稿快吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Dec 02 21:00:52 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589636, encodeId=2a1858963688, content=有要求字数要在5000以内吗凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!凱凱 2019-01-31 22:31:00 发表: submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, beContent=凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/edSY1qepX1ZvQ2va1f5T6pokTtL8znN1iclTQibflhWLyNAhELSEiamneoz9dNPY0iaxwf4bAiaFd27Aaicb8Ia9Qo4A/132, createdBy=0a5e2141609, createdName=豆们, createdTime=Fri Apr 24 00:00:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588315, encodeId=e23658831541, content=接收率这么高，约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrAfzjy5NbB6uHQuic53jMiazG25xatSfmLq4T2qc2T5WJuRhIicFcMDMTnLk5Awg75tic4NyBtawybmpCCiajrPVHg/132, createdBy=508c5311913, createdName=杨药师, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583184, encodeId=5a5458318457, content=应该都是约稿吧771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, beContent=771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18c096953, createdName=caowei561521, createdTime=Sun Jan 12 00:00:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581970, encodeId=ccb25819e06b, content=这个命中率是有问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f62b2484088, createdName=12464da8m54(暂无昵称), createdTime=Sun Dec 22 00:00:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581471, encodeId=aaf95814e1f5, content=请问有前辈在这本杂志上发过综述吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60882530625, createdName=771128365_61423734, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581285, encodeId=6e27581285b4, content=3400ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , beContent=ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581321, encodeId=1b33581321ce, content=你投过吗，处理稿件很慢么？一一一多 2019-12-11 00:00:00 发表: 3400, beContent=一一一多 2019-12-11 00:00:00 发表: 3400, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]

2019-12-11 一一一多

3400ybcfj 2019-12-10 00:00:00 发表:
问一下你稿号排到多少了

ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了

114 0

[GetPortalCommentsPageByObjectIdResponse(id=1016246, encodeId=859510162460e, content=偏重的研究方向：肿瘤 经验分享：本人新手，刚要投这个杂志，想问下各位前辈这个杂志有格式要求吗，感觉找了好久没有找到具体的格式要求，大家格式都是怎么改的呢？看以往的文献吗？急急急急！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Fri Sep 10 08:02:18 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800895, encodeId=a8bd800895b8, content=有谁投中过这个杂志？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Jul 02 14:23:56 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904388, encodeId=32e5904388c5, content=今年这个期刊审稿快吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/03/393d2058bac99c7312cd28b8b0426f23.jpg, createdBy=c7215235406, createdName=牵牛花开, createdTime=Wed Dec 02 21:00:52 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589636, encodeId=2a1858963688, content=有要求字数要在5000以内吗凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!凱凱 2019-01-31 22:31:00 发表: submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, beContent=凱凱 2019-01-31 发表:: 研究方向：Cancer;Angiogenesis;drug treatment 接收率：约95% 审稿时间：约1个月 submitted: 2018-8-3 2018-8-20 Major revision: 不給時間限制,revise後附上submitted編號即可 Revised: 2019-1-16 Accepted: 2019-1-28 值得一提2018-8-3投稿, 四個reviewers分別在8/6~8/11都回信了,只能說reviewer真的很給力!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/edSY1qepX1ZvQ2va1f5T6pokTtL8znN1iclTQibflhWLyNAhELSEiamneoz9dNPY0iaxwf4bAiaFd27Aaicb8Ia9Qo4A/132, createdBy=0a5e2141609, createdName=豆们, createdTime=Fri Apr 24 00:00:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588315, encodeId=e23658831541, content=接收率这么高，约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/QrAfzjy5NbB6uHQuic53jMiazG25xatSfmLq4T2qc2T5WJuRhIicFcMDMTnLk5Awg75tic4NyBtawybmpCCiajrPVHg/132, createdBy=508c5311913, createdName=杨药师, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583184, encodeId=5a5458318457, content=应该都是约稿吧771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, beContent=771128365_61423734 2019-12-14 00:00:00 发表: 请问有前辈在这本杂志上发过综述吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18c096953, createdName=caowei561521, createdTime=Sun Jan 12 00:00:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581970, encodeId=ccb25819e06b, content=这个命中率是有问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f62b2484088, createdName=12464da8m54(暂无昵称), createdTime=Sun Dec 22 00:00:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581471, encodeId=aaf95814e1f5, content=请问有前辈在这本杂志上发过综述吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60882530625, createdName=771128365_61423734, createdTime=Sat Dec 14 00:00:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581285, encodeId=6e27581285b4, content=3400ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , beContent=ybcfj 2019-12-10 00:00:00 发表: 问一下你稿号排到多少了 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581321, encodeId=1b33581321ce, content=你投过吗，处理稿件很慢么？一一一多 2019-12-11 00:00:00 发表: 3400, beContent=一一一多 2019-12-11 00:00:00 发表: 3400, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Wed Dec 11 00:00:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]

2019-12-11 一一一多

你投过吗，处理稿件很慢么？一一一多 2019-12-11 00:00:00 发表:
3400

一一一多 2019-12-11 00:00:00 发表: 3400

117 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务